We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Read MoreHide Full Article
Evaxion Biotech A/S (EVAX - Free Report) , along with its undisclosed partner, announced the successful completion of a series of large non-rodent animal infection studies, testing antigens from its investigational EVX-B1 vaccine candidate, which is being developed to treat Staphylococcus aureus (S. aureus) infection.
Per the companies, in the completed pre-clinical studies, treatment with EVX-B1 antigens significantly reduced the disease burden. Based on such positive results, Evaxion and its partner are currently discussing the path forward for the EVX-B1 vaccine development program.
EVAX’s EVX-B1 antigens have been developed utilizing the company’s proprietary AI-Immunology platform, which enables the identification of novel S. aureus antigens, allowing the development of a vaccine with the potential for broad protection against clinically relevant S. aureus strains.
Evaxion’s stock jumped 20.1% in the last trading session of Apr 2, in response to the encouraging news. In the past year, shares of EVAX have plunged 67.1% compared with the industry’s 6.9% decline.
Image Source: Zacks Investment Research
Results from the three separate pre-clinical studies conducted in clinically relevant large and non-rodent animals demonstrated that the EVX-B1 vaccine antigens significantly reduced S. aureus bacterial burden in a surgical site infection model. The administration of the vaccine also induced meaningful antigen-specific antibody titers in all vaccinated animals.
It was also observed that upon introduction to S. aureus bacteria, EVX-B1 vaccine antigens triggered a protective immune response in the animals, mimicking the immune response mechanism in human beings. The immune blood also showed its ability to neutralize clinically relevant S. aureus bacteria in the bloodstream, holding promise for positive data readout in early-stage clinical development.
Based on these findings, management believes that its EVX-B1 vaccine candidate has the potential to show efficacy against S. aureus infection in human beings, for which there are no other vaccines at present.
Per Evaxion, the S. aureus pathogen is responsible for infections of multiple organs and tissues, which can be profoundly severe or even cause death. Individuals with chronic conditions and patients undergoing surgeries are mostly prone to S. aureus infection.
According to the Centers for Disease Control and Prevention, there are 120,000 bloodstream infections associated with S. aureus in the United States annually, which represents a huge market opportunity for the company.
Evaxion Biotech A/S Sponsored ADR Price and Consensus
In the past 30 days, the Zacks Consensus Estimate for ADMA Biologics’ 2024 earnings per share (EPS) has remained constant at 30 cents. During the same period, the estimate for ADMA’s 2025 EPS has remained constant at 50 cents. In the past year, shares of ADMA have surged 100%.
ADMA beat estimates in three of the trailing four quarters and matched in one, delivering an average earnings surprise of 85%.
In the past 30 days, the Zacks Consensus Estimate for FibroGen’s 2024 loss per share has remained constant at $1.09. During the same period, the estimate for FibroGen’s 2025 loss per share has remained constant at 6 cents. In the past year, shares of FGEN have plunged 88.5%.
FGEN beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average negative surprise of 2.26%.
In the past 30 days, the Zacks Consensus Estimate for Adicet Bio’s 2024 loss per share has narrowed from $1.81 to $1.72. During the same period, the consensus estimate for Adicet’s 2025 loss per share has narrowed from $1.87 to $1.84. In the past year, shares of ACET have plunged 55.9%.
ACET beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average negative surprise of 0.17%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Evaxion Biotech A/S (EVAX - Free Report) , along with its undisclosed partner, announced the successful completion of a series of large non-rodent animal infection studies, testing antigens from its investigational EVX-B1 vaccine candidate, which is being developed to treat Staphylococcus aureus (S. aureus) infection.
Per the companies, in the completed pre-clinical studies, treatment with EVX-B1 antigens significantly reduced the disease burden. Based on such positive results, Evaxion and its partner are currently discussing the path forward for the EVX-B1 vaccine development program.
EVAX’s EVX-B1 antigens have been developed utilizing the company’s proprietary AI-Immunology platform, which enables the identification of novel S. aureus antigens, allowing the development of a vaccine with the potential for broad protection against clinically relevant S. aureus strains.
Evaxion’s stock jumped 20.1% in the last trading session of Apr 2, in response to the encouraging news. In the past year, shares of EVAX have plunged 67.1% compared with the industry’s 6.9% decline.
Image Source: Zacks Investment Research
Results from the three separate pre-clinical studies conducted in clinically relevant large and non-rodent animals demonstrated that the EVX-B1 vaccine antigens significantly reduced S. aureus bacterial burden in a surgical site infection model. The administration of the vaccine also induced meaningful antigen-specific antibody titers in all vaccinated animals.
It was also observed that upon introduction to S. aureus bacteria, EVX-B1 vaccine antigens triggered a protective immune response in the animals, mimicking the immune response mechanism in human beings. The immune blood also showed its ability to neutralize clinically relevant S. aureus bacteria in the bloodstream, holding promise for positive data readout in early-stage clinical development.
Based on these findings, management believes that its EVX-B1 vaccine candidate has the potential to show efficacy against S. aureus infection in human beings, for which there are no other vaccines at present.
Per Evaxion, the S. aureus pathogen is responsible for infections of multiple organs and tissues, which can be profoundly severe or even cause death. Individuals with chronic conditions and patients undergoing surgeries are mostly prone to S. aureus infection.
According to the Centers for Disease Control and Prevention, there are 120,000 bloodstream infections associated with S. aureus in the United States annually, which represents a huge market opportunity for the company.
Evaxion Biotech A/S Sponsored ADR Price and Consensus
Evaxion Biotech A/S Sponsored ADR price-consensus-chart | Evaxion Biotech A/S Sponsored ADR Quote
Zacks Rank and Stocks to Consider
Evaxion currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the drug/biotech industry are ADMA Biologics (ADMA - Free Report) , FibroGen (FGEN - Free Report) and Adicet Bio, Inc. (ACET - Free Report) . While ADMA sports a Zacks Rank #1 (Strong Buy), FGEN and ACET carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, the Zacks Consensus Estimate for ADMA Biologics’ 2024 earnings per share (EPS) has remained constant at 30 cents. During the same period, the estimate for ADMA’s 2025 EPS has remained constant at 50 cents. In the past year, shares of ADMA have surged 100%.
ADMA beat estimates in three of the trailing four quarters and matched in one, delivering an average earnings surprise of 85%.
In the past 30 days, the Zacks Consensus Estimate for FibroGen’s 2024 loss per share has remained constant at $1.09. During the same period, the estimate for FibroGen’s 2025 loss per share has remained constant at 6 cents. In the past year, shares of FGEN have plunged 88.5%.
FGEN beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average negative surprise of 2.26%.
In the past 30 days, the Zacks Consensus Estimate for Adicet Bio’s 2024 loss per share has narrowed from $1.81 to $1.72. During the same period, the consensus estimate for Adicet’s 2025 loss per share has narrowed from $1.87 to $1.84. In the past year, shares of ACET have plunged 55.9%.
ACET beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average negative surprise of 0.17%.